RxDoctor Payments Data

Scott Pollard, MD

Psychiatry · Cody, WYNPI 1851366314

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $285 and has fallen 57.5% since, to $121 in 2025.

$1,046in general payments, 2019–2025

Across 54 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$240
  • AbbVie$230
  • Neurocrine Biosciences, Inc.$139
  • Sunovion Pharmaceuticals Inc.$115
  • Alkermes, Inc.$87
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • plus $196 from 7 others

What the payments were for

  • Food & beverage$1,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,046 in reported general payments places this provider in the 85th percentile of 29 psychiatry providers in Wyoming.

See all psychiatry providers in Wyoming

Medicare billing

Part B allowed, 2024
$19,079
Medicare patients
77
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole60$97,684
TrintellixVortioxetine Hydrobromide56$35,381
LybalviOlanzapine/Samidorphan Malate15$22,898
VraylarCariprazine Hcl14$19,718
VyvanseLisdexamfetamine Dimesylate30$16,636
Lisdexamfetamine Dimesylate51$9,076
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl51$7,073
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate25$5,048
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine89$4,089
Asenapine Maleate12$3,016
Venlafaxine Hcl ErVenlafaxine Hcl29$2,758
Modafinil29$2,756
Lurasidone Hcl35$2,651
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine92$2,095
Duloxetine Hcl103$2,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$240$97,68460 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$37$52,01786 claims
Alkermes, Inc.Lybalvi$87$22,89815 claims
AbbVieVraylar$230$19,71814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 psychiatry providers in Wyoming.

Other psychiatry in Cody

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →